BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17332932)

  • 1. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck.
    Sauter A; Kloft C; Gronau S; Bogeschdorfer F; Erhardt T; Golze W; Schroen C; Staab A; Riechelmann H; Hoermann K
    Int J Oncol; 2007 Apr; 30(4):927-35. PubMed ID: 17332932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
    Tijink BM; Buter J; de Bree R; Giaccone G; Lang MS; Staab A; Leemans CR; van Dongen GA
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6064-72. PubMed ID: 17062682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma.
    Riechelmann H; Sauter A; Golze W; Hanft G; Schroen C; Hoermann K; Erhardt T; Gronau S
    Oral Oncol; 2008 Sep; 44(9):823-9. PubMed ID: 18203652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
    Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study.
    Rupp U; Schoendorf-Holland E; Eichbaum M; Schuetz F; Lauschner I; Schmidt P; Staab A; Hanft G; Huober J; Sinn HP; Sohn C; Schneeweiss A
    Anticancer Drugs; 2007 Apr; 18(4):477-85. PubMed ID: 17351401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
    Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
    J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo.
    Gurtner K; Hessel F; Eicheler W; Dörfler A; Zips D; Heider KH; Krause M; Baumann M
    Radiother Oncol; 2012 Mar; 102(3):444-9. PubMed ID: 22100655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
    J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q.
    Liebisch P; Eppinger S; Schöpflin C; Stehle G; Munzert G; Döhner H; Schmid M
    Haematologica; 2005 Apr; 90(4):489-93. PubMed ID: 15820944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients.
    Stroomer JW; Roos JC; Sproll M; Quak JJ; Heider KH; Wilhelm BJ; Castelijns JA; Meyer R; Kwakkelstein MO; Snow GB; Adolf GR; van Dongen GA
    Clin Cancer Res; 2000 Aug; 6(8):3046-55. PubMed ID: 10955783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.
    Tolcher AW; Ochoa L; Hammond LA; Patnaik A; Edwards T; Takimoto C; Smith L; de Bono J; Schwartz G; Mays T; Jonak ZL; Johnson R; DeWitte M; Martino H; Audette C; Maes K; Chari RV; Lambert JM; Rowinsky EK
    J Clin Oncol; 2003 Jan; 21(2):211-22. PubMed ID: 12525512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.
    Rodon J; Garrison M; Hammond LA; de Bono J; Smith L; Forero L; Hao D; Takimoto C; Lambert JM; Pandite L; Howard M; Xie H; Tolcher AW
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):911-9. PubMed ID: 18301896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
    Helft PR; Schilsky RL; Hoke FJ; Williams D; Kindler HL; Sprague E; DeWitte M; Martino HK; Erickson J; Pandite L; Russo M; Lambert JM; Howard M; Ratain MJ
    Clin Cancer Res; 2004 Jul; 10(13):4363-8. PubMed ID: 15240523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake.
    Scott AM; Lee FT; Jones R; Hopkins W; MacGregor D; Cebon JS; Hannah A; Chong G; U P; Papenfuss A; Rigopoulos A; Sturrock S; Murphy R; Wirth V; Murone C; Smyth FE; Knight S; Welt S; Ritter G; Richards E; Nice EC; Burgess AW; Old LJ
    Clin Cancer Res; 2005 Jul; 11(13):4810-7. PubMed ID: 16000578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck.
    Bastholt L; Specht L; Jensen K; Brun E; Loft A; Petersen J; Kastberg H; Eriksen JG
    Radiother Oncol; 2007 Oct; 85(1):24-8. PubMed ID: 17602769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
    Choi YJ; Chung JS; Shin HJ; Cho GJ; Wang SG; Lee BJ; Cho BM; Joo YD; Sohn CH
    J Laryngol Otol; 2008 Aug; 122(8):848-53. PubMed ID: 18047761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck.
    Colnot DR; Roos JC; de Bree R; Wilhelm AJ; Kummer JA; Hanft G; Heider KH; Stehle G; Snow GB; van Dongen GA
    Cancer Immunol Immunother; 2003 Sep; 52(9):576-82. PubMed ID: 14627130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer.
    Koppe M; Schaijk Fv; Roos J; Leeuwen Pv; Heider KH; Kuthan H; Bleichrodt R
    Cancer Biother Radiopharm; 2004 Dec; 19(6):720-9. PubMed ID: 15665619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck.
    Harrington KJ; El-Hariry IA; Holford CS; Lusinchi A; Nutting CM; Rosine D; Tanay M; Deutsch E; Matthews J; D'Ambrosio C; Turner SJ; Pandeshwara JS; Bourhis J
    J Clin Oncol; 2009 Mar; 27(7):1100-7. PubMed ID: 19171712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
    Papadopoulos KP; Goel S; Beeram M; Wong A; Desai K; Haigentz M; Milián ML; Mani S; Tolcher A; Lalani AS; Sarantopoulos J
    Clin Cancer Res; 2008 Nov; 14(21):7110-5. PubMed ID: 18981010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.